| 翻訳と辞書 |
| Jay Houston Hoofnagle ： ウィキペディア英語版 |
Jay Houston Hoofnagle
Jay Houston Hoofnagle is an American M.D. He is a leading expert in hepatotoxicity, hepatitis, cirrhosis and other diseases of the liver, and director of the Liver Disease Research Branch in the Division of Digestive Diseases and Nutrition at the National Institutes of Health.〔NIH, Jay H. Hoofnagle, M.D., http://www.niddk.nih.gov/about-niddk/staff-directory/extramural/jay-hoofnagle/pages/biography.aspx〕
Hoofnagle performed the first clinical trial on interferon for chronic hepatitis B. While it was believed that hepatitis was untreatable in the 1980s, Hoofnagle's trials at the National Institutes of Health using interferon during that period resulted in the first cures of hepatitis C infected patients.〔NIH, New NIDDK Branch Focuses on Liver Disease, Jul. 22, 2003, http://nihrecord.od.nih.gov/newsletters/07_22_2003/story05.htm〕 His graduate work is notable for elucidating serologic response to hepatitis infection and is included in many textbook descriptions of hepatitis infection as a classic piece of virology. Hoofnagle is the author of over 400 peer reviewed articles on liver diseases, and his Scopus h-index as of January 2014 is 69.〔Citation Overview, Hoofnagle, J.H. Jan. 2014 http://www.scopus.com/hirsch/author.url?stateKey=CTOF_471684749&accessor=CTO&origin=cto&display=hIndex&documentCount=438&txGid=6DAA952D0FD0EAAC14FC1BEFE10A5BD1.zQKnzAySRvJOZYcdfIziQ%3a40〕
==Career==
Hoofnagle leads the Liver Disease Branch at NIDDK,〔Peter Jaret, Expert Q&A, The Difficult Road of Hepatitis C Treatment, New York Times, Aug. 14, 2008 http://www.nytimes.com/ref/health/healthguide/esn-hepatitisC-expert.html〕 and has done so since he was tapped for the position in 2003.〔NIH, New NIDDK Branch Focuses on Liver Disease, Jul. 22, 2003, http://nihrecord.od.nih.gov/newsletters/07_22_2003/story05.htm〕 In this capacity, Hoofnagle oversees the Drug-Induced Liver Injury Network and (LiverTox ), a database that provides "comprehensive and unbiased information about drug induced liver injury caused by prescription and nonprescription drugs, herbal and dietary supplements."〔About Livertox, http://www.livertox.nih.gov/aboutus.html〕 Data produced from this network showed that dietary supplements account for nearly 20 percent of drug-induced liver injuries.〔Anahad O'Connor, Spike in Harm to Liver Is Tied to Dietary Aids, New York TImes, Dec. 13, 2013 http://www.nytimes.com/2013/12/22/us/spike-in-harm-to-liver-is-tied-to-dietary-aids.html?hp&_r=0〕
Prior to his current role, Hoofnagle was the Director of the Division of Digestive Diseases and Nutrition at the National Institute of Diabetes & Digestive & Kidney Diseases. Before joining the NIH, he was a senior scientist at the Hepatitis Branch, Division of Blood and Blood Products, Food and Drug Administration. Commissioned in the Public Health Service in 1978, he has risen to the rank of Lieutenant Commander.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Jay Houston Hoofnagle」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|